Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Manash Shankar Chatterjee"'
Autor:
Manash Shankar Chatterjee, Tomoko Freshwater, Dinesh P. de Alwis, Mallika Lala, Lokesh Jain, Tommy Ruosi Li, Anson K. Abraham, Kapil Mayawala, Vikram Sinha
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:200-209
Despite numerous publications emphasizing the value of dose finding, drug development in oncology is dominated by the mindset that higher dose provides higher efficacy. Examples of dose finding implemented by biopharmaceutical firms can change this m
Autor:
Martin Gutierrez, Anna Spreafico, Ding Wang, Talia Golan, Daniel Renouf, Mark Voskoboynik, Manash Shankar Chatterjee, Kishan J. Kapadia, Qi Liu, Gopala Kovvali, Leah Suttner, Ling Pang, Mei Chen, Anthony W. Tolcher
Publikováno v:
Journal of Clinical Oncology. 40:2505-2505
2505 Background: Immunoglobulin-like transcript 3 (ILT3) is an inhibitory receptor associated with immune tolerance and T-cell suppression within the tumor microenvironment. MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase 1 ev
Publikováno v:
Frontiers in Physiology, Vol 4 (2013)
Blood Systems Biology seeks to quantify outside-in signaling as platelets respond to numerous external stimuli, typically under flow conditions. Platelets can activate via GPVI collagen receptor and numerous G-protein coupled receptors (GPCRs) respon
Externí odkaz:
https://doaj.org/article/7b9d96523bc74551ba4846dc23a81bae
Autor:
Patricia Keegan, Chao Liu, Gideon M. Blumenthal, Malidi Ahamadi, Anna Georgieva Kondic, Manash Shankar Chatterjee, David C. Turner, Jiang Liu, Julie A. Stone, Claire Li, Sriram Subramaniam, Jingyu Yu, Rik de Greef, Atiqur Rahman, Hong Zhao, Brian Booth, Hongshan Li, Yaning Wang
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 44:403-414
Pembrolizumab is a monoclonal antibody that targets the programmed death-1 receptor to induce immune-mediated clearance (CL) of tumor cells. Originally approved by the US Food and Drug Administration in 2014 for treating patients with unresectable or
Autor:
Mark S. Forman, Anna Georgieva Kondic, Manash Shankar Chatterjee, Dinesh P. de Alwis, R de Greef, Julie A. Stone, David C. Turner, D Cutler, Malidi Ahamadi, Jeroen Elassaiss-Schaap
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:5-7
Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy-dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted t
Autor:
Ryan C. Vargo, Anne Chain, Larissa Wenning, Manash Shankar Chatterjee, Marissa F. Dockendorf, Ferdous Gheyas
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
Cardiovascular disease remains a significant global health burden, and development of cardiovascular drugs in the current regulatory environment often demands large and expensive cardiovascular outcome trials. Thus, the use of quantitative pharmacome
Autor:
Eliot A. Brinton, Antonio M. Gotto, Jennifer Moon, Philip J. Barter, Uma Kher, Sukrut Shah, Manash Shankar Chatterjee, Yang Liu, Christopher P. Cannon, Yale B. Mitchel, Xiujiang Susie Li, Sanskruti Vaidya, Hayes M. Dansky
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 19:543-549
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk of coron
Autor:
Jiayi Xu, Thomas Bateman, Patrick Andre, Wayne M. Geissler, Joseph M. Metzger, Harold B. Wood, Manash Shankar Chatterjee, Wendy Ankrom, Kung‐I Feng, Marija Tadin-Strapps, Dietmar Seiffert, Walter Strapps
Publikováno v:
Pharmacology Research & Perspectives
The benefits of novel oral anticoagulants are hampered by bleeding. Since coagulation factor IX (fIX) lies upstream of fX in the coagulation cascade, and intermediate levels have been associated with reduced incidence of thrombotic events, we evaluat
Autor:
Susana Miranda, L. Sun, Victor Moreno, Ruth Riisnaes, Richard D. Baird, Stan B. Kaye, William R. Schelman, Manash Shankar Chatterjee, Robert M Wenham, Carlo Toniatti, Johann S. de Bono, Heidrun Gevensleben, Robert Iannone, Christopher L. Carpenter, Lucy Hylands, Khin Thway, John W. Loughney, Aurelius Omlin, Shahneen Sandhu, Martin Forster, George Wilding, Nathan Kreischer
Publikováno v:
The Lancet. Oncology. 14(9)
Summary Background Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models
Autor:
David C. Turner, Dinesh P. de Alwis, David Dong, Rik de Greef, Malidi Ahamadi, Julie A. Stone, Kapil Mayawala, Anna Georgieva Kondic, Manash Shankar Chatterjee, Tomoko Freshwater
Publikováno v:
Cancer Research. 76:CT112-CT112
Background: The anti-PD-1 monoclonal antibody pembrolizumab has demonstrated durable antitumor activity against several advanced malignancies and is generally well tolerated. In the KEYNOTE-001, -002, and -006 trials, patients with advanced/metastati